ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Catty, rightly, or wrong, I got in early on the Libigel discoveries. I believed for several reasons that it was being set up as a revenue replacement for when AbbVie's Humira faced biosimilar competition originally though to be 2019 in the US but with successful patent litigation and signed deals AbbVie was able to delay the biosimilar launches in the US until 2023. There is still a chance that this may happen and I am willing to wait it out. For me as an early investor the reward is worth the risk. For those underwater obviously it is a much harder decision. This is why I am holding until 2023.